Predicting drug-drug interaction and optimal dosing regimens of rivaroxaban combined with ceritinib using physiologically based pharmacokinetic and pharmacodynamic modeling. (PubMed, Eur J Pharmacol) - Oct 9, 2026 - "Our model predicts that ceritinib co-administration substantially elevates rivaroxaban exposure and exploratory major bleeding risk. Dose adjustment, alternative therapies, or close clinical monitoring are recommended to ensure patient safety."
Journal • PK/PD data • Cardiovascular • Hematological Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Disease • Solid Tumor • Thrombosis
|
|
Jianwei Ren; Juhong Shi; Xiaohong Han; Xin Zheng; Yiyao Li
|